Iridex (IRIX) confirms that Local Coverage Determination) L37531, relating to Micro-Invasive Glaucoma Surgery, MIGS, was adopted as scheduled and will be effective for services performed on or after November 17, 2024. The Company has previously reported that it believes the reimbursement limitations created by the new LCD has potential to significantly increase physician interest in and use of Iridex’s advanced laser-based treatments for glaucoma. The new LCD clarifies that treatments performed using Iridex’s laser consoles and probes are not MIGS procedures, and thus, Iridex’s Cyclo G6 product family is unaffected by the new reimbursement limitations
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IRIX:
- Iridex Leadership Changes and Strategic Appointments
- Iridex Corporation’s Q3 2024 Financial Performance Overview
- IRIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Iridex CEO David Bruce to transition out of company, Patrick Mercer to succeed
- Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
